Kim Sung-A, Maeda Megumi, Murata Fumiko, Fukuda Haruhisa
Department of Health Care Administration and Management, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; St. Mary's Research Center, Kurume, Japan.
Department of Health Care Administration and Management, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Vaccine. 2025 Jan 1;43(Pt 2):126497. doi: 10.1016/j.vaccine.2024.126497. Epub 2024 Nov 5.
Post-COVID-19 conditions have emerged as a global health challenge. This study examined the long-term effects of COVID-19 vaccination on the incidence and risk of post-COVID-19 conditions in Japan.
This retrospective cohort study was conducted using a database comprising medical claims, COVID-19 case information, and vaccination records of persons residing in four Japanese municipalities. The cohort included COVID-19 cases diagnosed between August 2020 and December 2022. Participants were classified according to the duration between their most recent COVID-19 vaccination and COVID-19 occurrence (≥365 days, 150-364 days, and 14-149 days). The incidences of 36 post-COVID-19 conditions were monitored for 3, 5, and 8 months after infection. Cox proportional hazards models were used to calculate the risk of developing each post-COVID-19 condition within 8 months after infection according to vaccination status.
From among 84,464 participants, 9642 (11.4 %) developed post-COVID-19 conditions over 8 months. The 8-month risks of developing 28 (including various respiratory conditions, cardiovascular conditions, inflammatory and immune diseases, physical conditions, psychiatric conditions, and endocrine disorders) of the 36 target conditions were significantly lower when individuals had been recently vaccinated (14-149 days) before infection.
COVID-19 vaccination can reduce the incidence and risk of post-COVID-19 conditions if administered within 5 months before infection. Despite having the highest mean age and prevalence of comorbidities, individuals who were most recently vaccinated had a lower risk of developing post-COVID-19 conditions. These results provide important evidence for future COVID-19 vaccination strategies.
新冠后状况已成为一项全球健康挑战。本研究调查了新冠疫苗接种对日本新冠后状况的发病率及风险的长期影响。
本回顾性队列研究使用了一个数据库,该数据库包含居住在日本四个城市的人群的医疗理赔、新冠病例信息及疫苗接种记录。队列包括2020年8月至2022年12月期间确诊的新冠病例。参与者根据其最近一次新冠疫苗接种与新冠发病之间的时长进行分类(≥365天、150 - 364天和14 - 149天)。在感染后3、5和8个月监测36种新冠后状况的发病率。采用Cox比例风险模型根据疫苗接种状况计算感染后8个月内出现每种新冠后状况的风险。
在84464名参与者中,9642人(11.4%)在8个月内出现了新冠后状况。当个体在感染前最近接种过疫苗(14 - 149天)时,36种目标状况中的28种(包括各种呼吸道疾病、心血管疾病、炎症和免疫疾病、身体状况、精神疾病及内分泌紊乱)在8个月时发病的风险显著降低。
如果在感染前5个月内接种新冠疫苗,可降低新冠后状况的发病率及风险。尽管平均年龄最高且合并症患病率最高,但最近接种疫苗的个体出现新冠后状况的风险较低。这些结果为未来的新冠疫苗接种策略提供了重要证据。